Abstract
BackgroundTofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).ObjectivesAn evaluation of malignancies in the tofacitinib RA programme from the Phase (P) 2, P3, and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have